Merus Labs International Inc (MSL) Receives Consensus Recommendation of “Hold” from Analysts
Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is C$1.99.
A number of equities analysts have recently weighed in on the stock. Scotiabank lifted their price target on shares of Merus Labs International from C$1.25 to C$1.65 and gave the stock a “sector perform” rating in a research report on Friday, May 12th. TD Securities reduced their price target on shares of Merus Labs International from C$3.00 to C$1.65 and set a “tender” rating on the stock in a research report on Friday, May 12th. Finally, CIBC lifted their price target on shares of Merus Labs International from C$1.40 to C$1.65 in a research report on Monday, May 15th.
Shares of Merus Labs International (TSE:MSL) traded up 0.61% during mid-day trading on Tuesday, reaching $1.65. 21,976 shares of the company’s stock traded hands. The company’s 50 day moving average is $1.63 and its 200-day moving average is $1.30. Merus Labs International has a 52 week low of $0.95 and a 52 week high of $1.76.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.